Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction
关键词
抽象
日期
| 最后验证: | 12/31/2019 |
| 首次提交: | 10/09/2016 |
| 提交的预估入学人数: | 10/10/2016 |
| 首次发布: | 10/11/2016 |
| 上次提交的更新: | 01/24/2020 |
| 最近更新发布: | 01/27/2020 |
| 实际学习开始日期: | 12/29/2017 |
| 预计主要完成日期: | 12/29/2018 |
| 预计完成日期: | 12/29/2019 |
状况或疾病
干预/治疗
Drug: Clopidogrel
Drug: Ticagrelor
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Active Comparator: Ticagrelor Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose) | Drug: Ticagrelor Comparison of clopidogrel with another antiplatelet drug (ticagrelor) |
| Active Comparator: Clopidogrel Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose) | Drug: Clopidogrel Comparison of ticagrelor with another antiplatelet drug (clopidogrel) |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Age > 18 years - Informed consent to participate in the study - Percutaneous coronary intervention with stent implantation due to first ST-elevation myocardial infarction, or first non ST-elevation myocardial infarction - Administration of a loading dose of clopidogrel Exclusion Criteria: - Known coagulopathy - Known history of bleeding disorder - Suspicion of intracranial haemorrhage - Need for oral anticoagulation therapy - Administration of glycoprotein (GP) IIb-IIIa antagonists - Cardiogenic shock - Severe chronic renal failure (estimated glomerular filtration rate [eGFR] < 30 mL/min) - Severe liver insufficiency - Chronic dyspnea - Increased risk of bradycardia - Autoimmune disease - Infectious disease - Neoplasms - Pregnancy - Study drug intolerance - Co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors - Participation in any previous study with ticagrelor or clopidogrel |
结果
主要结果指标
1. Concentration of platelet extracellular vesicles [6 months following the beginning of antiplatelet therapy]
次要成果指标
1. Concentration of extracellular vesicles exposing fibrinogen [6 months following the beginning of antiplatelet therapy]
2. Concentration of extracellular vesicles exposing phosphatidylserine [6 months following the beginning of antiplatelet therapy]
3. Concentration of extracellular vesicles from endothelial cells [6 months following the beginning of antiplatelet therapy]
4. Concentration of extracellular vesicles from leukocytes [6 months following the beginning of antiplatelet therapy]
